Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY.
馬薩諸塞州劍橋，2024年5月13日（GLOBE NEWSWIRE）——致力於提供新一類差異化一次性治療遺傳療法的生物技術公司Prime Medicine, Inc.（納斯達克股票代碼：PRME）今天宣佈，Prime Medicine首席財務官艾倫·雷恩醫學博士將參加2024年5月20日星期一在納斯達克舉行的H.C. Wainwright第二屆年度BioConnect投資者大會的爐邊談話，美國東部時間下午 4:30，紐約州紐約。
A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the presentation.
爐邊談話的網絡直播將在公司網站新聞與事件欄目的 “活動與演講” 下提供 www.primemedicine.com。 網絡直播的重播將在演講結束後的90天內在Prime Medicine網站上播出。
About Prime Medicine
關於普瑞米醫學
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing's versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine 是一家領先的生物技術公司，致力於爲患者創造和提供下一代基因編輯療法。該公司正在部署其專有的Prime Editing平台，這是一種多功能、精確和高效的基因編輯技術，以開發一類新的差異化一次性治療遺傳療法。Prime Editors旨在僅在基因的正確位置進行正確的編輯，同時最大限度地減少不必要的DNA修改，它有可能修復幾乎所有類型的基因突變，並適用於許多不同的組織、器官和細胞類型。總而言之，Prime Editing的多功能基因編輯能力可以爲數千種潛在適應症開啓機會。
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular. Across each core area, Prime Medicine's initial focus is on genetic diseases with a fast, direct path to treating patients, and those with high unmet need not currently addressable using other gene editing approaches. Over time, the Company intends to maximize Prime Editing's broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
Prime Medicine目前正在推進圍繞核心重點領域組織的多元化研究性治療項目組合：血液學和免疫學、肝臟、肺部、眼部和神經肌肉學。在每個核心領域，Prime Medicine最初的重點是遺傳性疾病，爲患者提供快速、直接的治療途徑，而那些未得到滿足的患者目前無法使用其他基因編輯方法來解決的需求。隨着時間的推移，該公司打算最大限度地發揮Prime Editing廣泛而多功能的治療潛力，將業務擴展到其最初研發的遺傳疾病之外，可能包括免疫疾病、癌症、傳染病，並針對共同影響數百萬人的常見疾病中的遺傳風險因素。欲了解更多信息，請訪問 www.primemedicine.com.
2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
2024 Prime Medicine, Inc. 版權所有。PRIME MEDICINE、Prime Medicine 徽標和 PASSIGE 是 Prime Medicine, Inc. 的商標。此處提及的所有其他商標均爲其各自所有者的財產。
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
投資者聯繫人
漢娜·德雷西維奇
斯特恩投資者關係有限公司
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
媒體聯繫人
丹·佈德威克，1AB
dan@1ABmedia.com
譯文內容由第三人軟體翻譯。